Business Wire

The Digital Cooperation Organization Hosted Its First Collaborative Roundtable With Social Media, Technology Companies, and Digital Platforms to Combat the Spread of Online Misinformation

28.8.2024 22:45:00 EEST | Business Wire | Press release

Share

The Digital Cooperation Organization (DCO), a global multilateral organization committed to enabling digital prosperity for all by accelerating the sustainable and inclusive growth of the digital economy, hosted a strategic roundtable discussion with major technology companies, and social media and digital platform representatives to address the societal impact of the spread of online misinformation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240828374432/en/

Representatives from social media, technology companies, and digital platforms at the DCO HQ (Photo AETOSWire)

Building on the series of global roundtables conducted in 2023 as part of the “combating online misinformation” Digital Space Accelerators, this roundtable continuous the DCO’s ongoing efforts to combat online misinformation. Representatives from Google, LinkedIn, Meta and TikTok participated as key stakeholders to discuss this crucial issue affecting the digital world.

The roundtable, held at the DCO headquarters in Riyadh, Saudi Arabia, aimed to identify challenges and propose innovative solutions to foster trust and safeguard the digital economy. The participation of representatives from social media and digital platforms underscored the importance of the roundtable, providing a crucial platform for stakeholders to exchange perspectives and explore collaborative actions to combat online misinformation.

The discussions aimed to create an ongoing dialogue on the gravity of online misinformation as both a societal problem and a challenge to the digital economy. It also provided a platform for stakeholders to bridge their perspectives and work together to combat online misinformation, thereby ensuring a trustworthy digital information ecosystem.

"The exchange of ideas and insights from leading platforms has been invaluable. The key takeaway from the discussion was the importance of cooperation through a multistakeholder approach to combat online misinformation, which aligns with the DCO’s mission. We are confident that the outcomes of this roundtable will pave the way for a more informed and resilient digital society, and we look forward to our next collaborative roundtable to enable digital prosperity for all", said Alaa Abdulaal, Chief of the Digital Economy Foresight department at the Digital Cooperation Organization.

Sarah Al-Husseini, Head of Government Affairs & Public Policy, KSA at Google, said: “People come to Google because they trust they will be able to find high quality information, which is why we take our commitment to combating misinformation through our products and our content policies very seriously. We work hard to retain that trust - designing our systems for quality and ensuring users are given access to a range of information from different voices and the tools to know what they can trust. We do not do it alone; in addition to continuously adapting our policies and technologies to prevent abuse, we openly share our technology and collaborate with experts to drive the industry forward and create a safer internet for everyone.”

Ranim Alamin, Strategic Government Partnerships Head, KSA at LinkedIn, said: “Taking part in the DCO's strategic roundtable offered us a valuable opportunity to discuss one of the more pressing issues in the digital world: Misinformation. The conversations we had with representatives from various leading platforms underscored the importance of a united approach to foster trust. We are committed to working together to build a more trusted and resilient digital information ecosystem.”

Tom Bonsundy-O'Bryan, Misinformation Policy, EMEA Lead at Meta, said: “We were glad to attend this roundtable organized by the DCO and remain deeply committed to tackling misinformation - balancing our values of expression, safety, authenticity and privacy.”

Hatem Samman, Executive Director of Government Relations & Public Policy, KSA at TikTok, said: “At TikTok, we are committed to fostering a secure and trustworthy digital environment for the community. This roundtable provided an essential platform for discussing innovative strategies and collaborative actions to combat misinformation. By working together, we can create a safe, authentic space where people can discover content that is original and engage with people who are authentic.”

The Digital Cooperation Organization remains committed to fostering a collaborative approach to combating misinformation and ensuring the growth of the digital economy. The DCO looks forward to continuing this impactful work with its partners in the social media and digital platform space.

*Source: AETOSWire

View source version on businesswire.com: https://www.businesswire.com/news/home/20240828374432/en/

Contacts

Ahmed Bayouni
Media@dco.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye